GlassScriptPhysician profile
William Z Bartels
NPI 1689650947
$5,181.37
in general payments reported to CMS, 2019-2025
26 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $506 · 2021: $487 · 2022: $600 · 2023: $726 · 2024: $1,013 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,094.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $770.36 | 2023-2025 | Infuse, Miebo, Vyzulta |
| Abbvie INC. | $533.35 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Harrow Eye, LLC | $495.90 | 2024-2025 | Vevye, Flarex |
| Sun Pharmaceutical Industries INC. | $479.60 | 2019-2025 | Cequa |
| Allergan, INC. | $469.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $421.48 | 2020-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $315.23 | 2020-2023 | Star S4 Ir, Tecnis Iol |
| Coopervision INC. | $292.94 | 2019-2025 | Myday Contact Lens, Biofinity Contact Lens |
| Tarsus Pharmaceuticals, INC. | $194.40 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $189.69 | 2019 | |
| Mallinckrodt Hospital Products INC. | $177.13 | 2024-2025 | Acthar |
| Sight Sciences, INC. | $157.82 | 2022-2025 | Tearcare System |
| Genmab U.S., INC. | $124.84 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $101.08 | 2020 | |
| Eyevance Pharmaceuticals LLC | $76.30 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $57.29 | 2023-2024 | Precision 1, Eysuvis |
| Kala Pharmaceuticals, INC. | $46.57 | 2021-2022 | |
| Astellas Pharma US INC | $44.66 | 2024-2025 | Izervay |
| Johnson & Johnson Vision Care, INC. | $41.35 | 2019-2024 | |
| Abb Con-Cise Optical Group LLC | $39.14 | 2024 | Contact Lens, Spectacle Lenses |
| Glaukos Corporation | $32.32 | 2024 | Idose |
| Lumenis, INC | $31.04 | 2021 | |
| Oyster Point Pharma, INC. | $28.99 | 2022-2024 | Ryzumvi, Tyrvaya |
| Quidel Corporation | $26.59 | 2019 | |
| Biotissue Holdings INC. | $18.17 | 2019 | |
| Maculogix, INC. | $16.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bartels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.